News: Simtuzumab

We provide the latest news and info on Simtuzumab


ValueWalk

Gilead Halts Study of Simtuzumab in Patients With Pulmonary Fibrosis
Managed Care magazine
Gilead Sciences has announced that the company is stopping its mid-stage trial of the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis. The decision follows an analysis of unblinded efficacy and safety ...
Gilead Sciences Down; Daiwa SB Investments Cuts StakeValueWalk

all 2 news articles »

Published on Monday 8th of February 2016 06:08:08 AM Read more...


Pulmonary Fibrosis News

Phase II Trial for Gilead's IPF Therapy Simtuzumab Terminated After DMC Recommendation
Pulmonary Fibrosis News
Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the ...

Published on Monday 8th of February 2016 06:08:08 AM Read more...
Published on Monday 8th of February 2016 06:08:08 AM Read more...


Motley Fool

1 Company Gilead Sciences Should Consider Buying Right Now
Motley Fool
It has TAF in late-stage trials for hepatitis B, as well as GS-4774 and GS-9620 in midstage studies for HBV, but it's also studying simtuzumab and GS-4997 in midstage trials for NASH. Having what could aptly be summarized as three of the top potential ...

and more »

Published on Monday 8th of February 2016 06:08:08 AM Read more...


Gilead (GILD) Simtuzumab Advancement in NASH an 'Incremental Positive', Jefferies Says
StreetInsider.com
Jefferies analyst Brian Abrahams said they have confirmed that the interim 48-week futility analysis for antifibrotic pipeline antibody simtuzumab in NASH has been completed and the ph.II studies are continuing. The sees this as an incremental positive ...

and more »

Published on Monday 8th of February 2016 06:08:08 AM Read more...


Pulmonary Fibrosis News

Simtuzumab (GS-6624)
Pulmonary Fibrosis News
Simtuzumab, also known as GS-6624 is a pipeline drug being developed by Gilead Sciences for the treatment of Idiopathic Pulmonary Fibrosis and related conditions like Cirrhosis developed from Non-Alcoholic Steato Hepatitis (NASH).

Published on Monday 8th of February 2016 06:08:08 AM Read more...


Motley Fool

Gilead Sciences Takes 2 Steps Forward and 1 Step Back
Motley Fool
More recently, independent data monitors informed Gilead that simtuzumab would miss the mark again, this time in idiopathic pulmonary fibrosis, a fatal disease characterized by scarring of the lungs. Gilead was fortunate in that it was able to ...

and more »

Published on Monday 8th of February 2016 06:08:08 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts